Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Free Cash Flow (2019 - 2025)

C4 Therapeutics' Free Cash Flow history spans 7 years, with the latest figure at -$22.7 million for Q4 2025.

  • For Q4 2025, Free Cash Flow fell 26.77% year-over-year to -$22.7 million; the TTM value through Dec 2025 reached -$99.1 million, down 51.7%, while the annual FY2025 figure was -$99.3 million, 51.98% down from the prior year.
  • Free Cash Flow reached -$22.7 million in Q4 2025 per CCCC's latest filing, up from -$31.0 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$5.0 million in Q2 2024 to a low of -$33.3 million in Q1 2023.
  • Average Free Cash Flow over 5 years is -$23.5 million, with a median of -$23.6 million recorded in 2022.
  • Peak YoY movement for Free Cash Flow: skyrocketed 73.79% in 2024, then crashed 141.77% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at -$25.7 million in 2021, then fell by 19.27% to -$30.6 million in 2022, then increased by 26.59% to -$22.5 million in 2023, then rose by 20.23% to -$17.9 million in 2024, then fell by 26.77% to -$22.7 million in 2025.
  • Per Business Quant, the three most recent readings for CCCC's Free Cash Flow are -$22.7 million (Q4 2025), -$31.0 million (Q3 2025), and -$12.1 million (Q2 2025).